---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-223802"
form_type: "8-K"
ticker: null
cik: "0001850079"
company_name: "Telesis Bio Inc."
filed_at: "2023-08-29T23:59:59+00:00"
generated_at: "2026-06-11T02:32:25.363577+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Telesis Bio appoints William Kullback as CFO effective August 28, 2023

## Summary
- Kullback's base salary set at $430,000 with target bonus of 50% of salary and $100,000 signing bonus.
- Company will recommend a grant of an option to purchase 300,000 shares of common stock.
- Previously CFO at BioLegend, where he led its $5.25B sale to Revvity (PerkinElmer).
- Kullback also served as CFO at Lombard Medical (Nasdaq: EVAR) from 2014 to 2017.

## SEC filing metadata
- accession: 0001193125-23-223802
- form_type: 8-K
- cik: 0001850079
- company_name: Telesis Bio Inc.
- filed_at: 2023-08-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850079/000119312523223802/0001193125-23-223802-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850079/000119312523223802/d333931d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-223802
- JSON: https://secwatch.observer/filing/0001193125-23-223802.json
- Plain text: https://secwatch.observer/filing/0001193125-23-223802.txt

## Key facts
- Executive change
  William Kullback was appointed as Chief Financial Officer at Telesis Bio Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On August 28, 2023, the Company appointed William Kullback, age 63, as Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850079/000119312523223802/0001193125-23-223802-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.